Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation.

PubWeight™: 5.54‹?› | Rank: Top 1%

🔗 View Article (PMC 2962586)

Published in Lancet on July 16, 1994

Authors

P Fontes1, A S Rao, A J Demetris, A Zeevi, M Trucco, P Carroll, W Rybka, W A Rudert, C Ricordi, F Dodson

Author Affiliations

1: Department of Surgery, Pittsburgh Transplant Institute, University of Pittsburgh Medical Centre, PA 15213.

Articles citing this

Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59

The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56

Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52

Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33

Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30

Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29

Current status of intestinal transplantation in children. J Pediatr Surg (1998) 1.28

Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg (1999) 1.24

Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. Transplant Proc (1995) 1.24

Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19

Immune status of recipients following bone marrow-augmented solid organ transplantation. Transplantation (1995) 1.18

Progress in renal transplantation. A single center study of 3359 patients over 25 years. Ann Surg (1995) 1.07

Augmentation of chimerism with perioperative donor bone marrow infusion in organ transplant recipients: a 44 month follow-up. Transplant Proc (1997) 1.07

Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. Liver Transpl (2000) 1.07

In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation (1995) 1.06

The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest (1997) 1.02

Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. Transplant Proc (1995) 1.00

Concomitant infusion of unmodified donor bone marrow into unconditioned recipients of intestinal allografts. Transplant Proc (1996) 1.00

Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc (1995) 0.99

Perioperative donor bone marrow infusion augments chimerism in heart and lung transplant recipients. Ann Thorac Surg (1995) 0.98

Combined simultaneous kidney/bone marrow transplantation. Transplantation (1995) 0.98

Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97

Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. Rev Diabet Stud (2010) 0.96

An attempt to reverse diabetes by delayed islet cell transplantation in humans. Transplant Proc (1997) 0.94

Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Transplant Proc (1999) 0.92

Explanation for loss of the HLA matching effect. Transplant Proc (1995) 0.91

Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc (1996) 0.90

Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89

A clinical trial combining donor bone marrow infusion and heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg (2000) 0.89

Liver transplants contribute to their own success. Nat Med (1996) 0.89

Development and validation of a procedure to isolate viable bone marrow cells from the vertebrae of cadaveric organ donors for composite organ grafting. Cytotherapy (2011) 0.87

Bone marrow augmentation in renal transplant recipients. Transplant Proc (1998) 0.86

Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant Proc (1998) 0.86

Infusion of donor leukocytes to induce tolerance in organ allograft recipients. J Leukoc Biol (1999) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Three years of follow-up of bone marrow-augmented organ transplant recipients: the impact on donor-specific immune modulation. Transplant Proc (1997) 0.84

Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. Transplantation (1997) 0.84

Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. Transplant Proc (1995) 0.83

TGF-beta 1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells. Transpl Immunol (1996) 0.83

Effect in supralethally irradiated rats of granulocyte colony-stimulating factor and lisofylline on hematopoietic reconstitution by syngeneic bone marrow or whole organ passenger leukocytes. Transplantation (1997) 0.83

The future of transplantation: with particular reference to chimerism and xenotransplantation. Transplant Proc (1997) 0.83

The efficacy of daclizumab for intestinal transplantation: preliminary report. Transplant Proc (2000) 0.82

Clinical implementation of a procedure to prepare bone marrow cells from cadaveric vertebral bodies. Regen Med (2011) 0.82

Microchimerism in promoting graft acceptance in clinical transplantation. Curr Opin Organ Transplant (2011) 0.81

Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg (2000) 0.80

A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. Transplantation (2013) 0.80

Upper extremity transplantation: current concepts and challenges in an emerging field. Curr Rev Musculoskelet Med (2014) 0.79

Therapeutic advances in immunosuppression. Clin Exp Immunol (1994) 0.79

Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation (1997) 0.79

The dichotomous functions of passenger leukocytes in solid-organ transplantation. Adv Nephrol Necker Hosp (1995) 0.79

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant (1997) 0.79

Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates. Am J Transplant (2008) 0.79

Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol (2002) 0.78

Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow transplantation. Transplant Proc (1995) 0.78

Translating transplantation tolerance in the clinic: where are we, where do we go? Clin Exp Immunol (2009) 0.78

The two-way paradigm of transplantation immunology. Clin Immunol Immunopathol (1996) 0.78

Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78

Peter Brian Medawar: father of transplantation. J Am Coll Surg (1995) 0.78

Tolerance after solid organ and hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.77

Human-to-baboon bone marrow transplantation after conditioning with nonlethal irradiation. Transplant Proc (1994) 0.77

Clinical intestinal transplantation in 1998: Pittsburgh experience. Acta Gastroenterol Belg (1999) 0.77

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

The birth of clinical organ transplantation. J Am Coll Surg (2001) 0.76

Kidney/Bone Marrow Transplantation. Dial Transplant (1996) 0.76

Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients: improved graft function and higher graft survival. Chimerism (2013) 0.76

Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc (2001) 0.76

Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76

Donor-derived peripheral mononuclear cell DNA is associated with stable kidney allograft function: a randomized controlled trial. Chimerism (2012) 0.76

Chimerism after organ transplantation. Curr Opin Nephrol Hypertens (1997) 0.76

Xenobiotics, chimerism and the induction of tolerance following organ transplantation. Ther Immunol (1994) 0.76

The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Postgrad Med J (1997) 0.75

Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant Alone. J Am Heart Assoc (2015) 0.75

Evidence for engraftment of human bone marrow cells in non-lethally irradiated baboons. Transplantation (1997) 0.75

The bidirectional paradigm of transplant immunology. Ann N Y Acad Sci (1995) 0.75

Perioperative donor bone marrow infusion in recipients of organ allografts. Transplant Proc (1997) 0.75

Donor bone marrow infusion in liver recipients: effect on the occurrence of acute cellular rejection. Transplant Proc (2001) 0.75

Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc (1999) 0.75

The basis of allograft acceptance. Forum (Genova) (1997) 0.75

Hematopoietic cell transplantation for tolerance induction. Cytotechnology (1998) 0.75

Formation of microchimerism in rat small bowel transplantation by splenocyte infusion. World J Gastroenterol (2006) 0.75

Articles cited by this

Actively acquired tolerance of foreign cells. Nature (1953) 19.82

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Automated method for isolation of human pancreatic islets. Diabetes (1988) 8.23

THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Detection of Y chromosome sequences in Turner's syndrome by Southern blot analysis of amplified DNA. Lancet (1993) 2.65

Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32

Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84

Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: clinical and immunological studies. Ann Surg (1982) 1.44

Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29

Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet (1994) 1.18

A seven-year experience with donor-specific blood transfusions. Results and considerations for maximum efficacy. Transplantation (1985) 1.17

Total lymphatic irradiation and bone marrow in human heart transplantation. Ann Thorac Surg (1984) 1.11

Total lymphoid irradiation--current status. Transplant Proc (1989) 0.99

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science (2000) 5.38

Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci U S A (1995) 5.25

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Liver transplantation (1). N Engl J Med (1989) 4.53

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Baboon-to-human liver transplantation. Lancet (1993) 4.01

The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet (1997) 3.70

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature (1992) 3.39

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med (1995) 3.16

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11

Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res (1999) 3.05

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology (1996) 2.95

Liver transplantation (2). N Engl J Med (1989) 2.93

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Detection of Y chromosome sequences in Turner's syndrome by Southern blot analysis of amplified DNA. Lancet (1993) 2.65

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45

Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases. J Bone Joint Surg Am (1984) 2.31

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28

Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature (1994) 2.25

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci U S A (1988) 2.19

Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17

A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14

Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene (2005) 2.11

Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11

Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. Proc Natl Acad Sci U S A (1996) 2.10

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Pneumothorax in the newborn. Neonatal Netw (1991) 2.03

Shipment of human islets for transplantation. Am J Transplant (2007) 2.01